Zoe, a nutrition science startup based in London, UK, has successfully secured an impressive $15 million in a Series B extension funding round. This significant investment was facilitated by Coefficient Capital, a venture firm known for supporting innovative companies in the health and wellness sector. With this latest round of funding, Zoe has now accumulated a remarkable total of $118 million in investments, which underscores the confidence investors have in the company’s potential to revolutionize the way individuals approach their health and nutrition.
The primary objective of Zoe with this new funding is to enhance its operations and broaden its business reach, extending its innovative solutions to a larger audience.
Under the leadership of CEO Jonathan Wolf, Zoe has developed a unique approach that combines at-home test kits with personalized nutrition programs. Users can engage in a comprehensive analysis of their health through microbiome assessment, blood testing, and food logging, as well as continuous blood sugar monitoring. This holistic approach empowers individuals to gain insights into their health, making it easier to tailor their nutrition accordingly.
A standout feature of Zoe's offering is its at-home poop test, which is patent pending and touted as one of the most advanced analyses available on the market today. Utilizing deep shotgun sequencing technology, Zoe is able to pinpoint specific beneficial and detrimental gut bacteria linked to metabolic health outcomes. Additionally, their suite of tools includes a finger-prick blood test, test cookies, and an optional blood sugar sensor, providing a comprehensive picture of an individual’s blood sugar and fat levels after meals. After a six-week processing period, users receive their detailed test results along with a personalized analysis that elucidates the implications for their health and wellness, ultimately fostering a more informed approach to nutrition and dietary choices.
Click here for a full list of 6,528+ startup investors in the UK